Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.35 |
| ▸ | ITGAL | P20701 | 9/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24483838 | 0.93 | HDAC1 (0.35) | MAPTTP53ITGB2ICAM1ITGAL | |
| SCHEMBL22845445 | 0.91 | MAPT (0.35) | MAPTTP53ITGB2ICAM1ITGAL | |
| SCHEMBL24173421 | 0.91 | ALDH1A1 (0.36) | MAPTTP53ALDH1A1LMNAGAA | |
| SCHEMBL22845444 | 0.91 | MAPT (0.34) | MAPTTP53HDAC1HDAC10HDAC8 | |
| SCHEMBL26842658 | 0.90 | MAPT (0.35) | MAPTTP53ITGB2ICAM1ITGAL | |
| SCHEMBL22845333 | 0.89 | LMNA (0.38) | TP53POLBLMNAGAA | |
| SCHEMBL22845425 | 0.89 | MTHFD2 (0.33) | MAPTTP53ALDH1A1LMNAGAA | |
| SCHEMBL22830614 | 0.88 | PRKAA2 (0.34) | MAPTTP53ITGB2ICAM1ITGAL | |
| SCHEMBL22845500 | 0.88 | MTHFD2 (0.35) | MAPTTP53ITGB2ICAM1ITGAL | |
| SCHEMBL22845291 | 0.87 | ALDH1A1 (0.35) | ITGB2ICAM1ITGALHDAC1HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPT 651/4885TP53 1710/4885ITGB2 4475/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPT 651/4885TP53 1710/4885ITGB2 4475/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPT 651/4885TP53 1710/4885ITGB2 4475/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPT 651/4885TP53 1710/4885ITGB2 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.